Immunic (IMUX) to Release Quarterly Earnings on Thursday

Key Points

• Immunic (NASDAQ:IMUX) is set to release its Q1 2025 earnings results on August 14th, with analysts expecting a loss of ($0.19) per share.
• The company reported a loss of ($0.25) per share in its previous quarterly results, aligning with analysts' predictions.
• Several analysts have given Immunic a "buy" rating, with price targets ranging from $5.00 to $10.00 per share, reflecting positive investor sentiment.

Immunic (NASDAQ:IMUX - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Trading Down 0.2%

Immunic stock opened at $0.98 on Thursday. Immunic has a 12 month low of $0.56 and a 12 month high of $2.11. The company has a market capitalization of $93.85 million, a price-to-earnings ratio of -0.80 and a beta of 1.39. The business's fifty day simple moving average is $0.83 and its two-hundred day simple moving average is $0.97.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immunic stock. Jane Street Group LLC increased its stake in Immunic, Inc. (NASDAQ:IMUX - Free Report) by 279.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 207,401 shares of the company's stock after purchasing an additional 152,726 shares during the quarter. Jane Street Group LLC owned 0.22% of Immunic worth $226,000 at the end of the most recent quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on IMUX shares. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Immunic in a research report on Thursday, May 1st. B. Riley restated a "buy" rating and set a $5.00 price objective (down from $6.00) on shares of Immunic in a research note on Friday, May 23rd. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Immunic in a report on Wednesday, June 25th. Finally, William Blair reiterated an "outperform" rating on shares of Immunic in a report on Friday, May 16th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Immunic currently has an average rating of "Buy" and an average price target of $7.50.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.